NSAIDs with Lower GI and CV Risk Profiles

NSAIDs with Lower GI Risk

Ibuprofen at low analgesic doses has less ulcerogenic potential compared to NSAIDs that require high anti-inflammatory doses for adequate analgesia, such as piroxicam, according to the American Gastroenterological Association 1
Etodolac and nabumetone demonstrate superior GI safety profiles compared to other traditional NSAIDs, as recommended by the American College of Gastroenterology 2, 3
NSAIDs with short half-lives and less enterohepatic circulation generally cause fewer GI complications, as stated by the American College of Gastroenterology 2
NSAIDs with prominent enterohepatic circulation and prolonged half-lives, such as sulindac, indomethacin, piroxicam, and ketorolac, are linked to greater GI toxicity, according to the American Gastroenterological Association 2
Full anti-inflammatory doses of any NSAID, including ibuprofen, increase GI bleeding risk to levels comparable with other NSAIDs, as reported by the American College of Gastroenterology 1
Concomitant use of aspirin with any NSAID increases GI bleeding risk more than 10-fold compared to using either agent alone, as warned by the American Heart Association 2, 4

Naproxen has the most favorable cardiovascular risk profile among NSAIDs, according to the American College of Cardiology 5, 4
COX-2 selective inhibitors, such as celecoxib, are associated with increased cardiovascular risk, as reported by the American Geriatrics Society 6
Rofecoxib and valdecoxib were withdrawn from the market due to associated risk of adverse cardiovascular events, as stated by the American Geriatrics Society 6

For patients with high GI risk and low CV risk, the first choice is a COX-2 selective inhibitor, such as celecoxib, as recommended by the American College of Gastroenterology 7, 8
For patients with high CV risk and low GI risk, the first choice is naproxen, which has the lowest CV risk, as recommended by the American College of Cardiology 4
For patients with both high GI and CV risk, consider alternatives to NSAIDs when possible, and if NSAID is necessary, use naproxen plus a proton pump inhibitor, as suggested by the American College of Gastroenterology 1, 8

Use the lowest effective dose for the shortest duration possible, as recommended by the American College of Gastroenterology 8, 9
Consider H. pylori testing and eradication in high-risk patients before starting long-term NSAID therapy, as suggested by the American College of Gastroenterology 8, 4
Add proton pump inhibitor therapy for patients at moderate to high risk of GI complications, as recommended by the American College of Gastroenterology 8, 9
Avoid combination NSAID therapy, including over-the-counter NSAIDs with prescription NSAIDs, as warned by the American College of Gastroenterology 8

The American Academy of Family Physicians recommends that ketorolac be used with caution in patients over 60 years old without gastroprotection 10
Patients with a history of previous peptic ulcer disease have an increased risk of GI events, with an odds ratio of up to 13.5 11
The American Gastroenterological Association suggests that concomitant use of corticosteroids, anticoagulants, or antiplatelet agents increases the risk of GI complications 12
Patients with cardiovascular disease or renal insufficiency are at higher risk of GI complications 13

The American College of Gastroenterology recommends instituting gastroprotection with proton pump inhibitors (PPIs) or misoprostol (600 mg/day if tolerated) for patients requiring ketorolac who have moderate-to-high GI risk 14, 10
H2-receptor antagonist therapy is inadequate for protection 14
The National Comprehensive Cancer Network suggests considering H. pylori testing and eradication in high-risk patients, though eradication alone is insufficient without concurrent gastroprotection 14, 12

The American Family Physician recommends avoiding ketorolac entirely in high GI risk patients (≥3 risk factors, prior ulcer, elderly on anticoagulants) and selecting alternative NSAIDs with better GI safety profiles combined with PPIs 11
If ketorolac is deemed essential, it should be used only with aggressive gastroprotection (PPI plus misoprostol) and limited to the absolute minimum duration 12
Ketorolac is contraindicated in patients with a history of ulcer complications, and all NSAIDs should be avoided if possible 12

El ketorolaco tiene un riesgo de sangrado gastrointestinal significativamente más alto que otros AINEs debido a su potente inhibición de la COX-1, su vida media prolongada, y su circulación enterohepática prominente, lo que resulta en exposición mucosa prolongada, siendo hasta 5 veces más gastrotóxico que otros AINEs 15
La historia de úlcera péptica, sangrado o perforación aumenta el riesgo de sangrado GI hasta 13.5 veces 15
El uso concomitante con anticoagulantes o antiagregantes plaquetarios aumenta sinérgicamente el riesgo de sangrado 16
El uso combinado de ketorolaco con aspirina aumenta el riesgo de sangrado GI más de 10 veces comparado con usar cualquiera de los agentes solo 17

La American College of Cardiology recomienda evitar el uso de ketorolaco en pacientes con alto riesgo de sangrado GI y considerar alternativas como inhibidores selectivos de COX-2 o naproxeno con protección gastrointestinal 17
La dosis más baja necesaria de ketorolaco debe ser utilizada para controlar el dolor y limitar la duración a los mínimos días posibles (máximo 5 días) 18
En pacientes de alto riesgo GI que requieren ketorolaco, se debe instituir gastroprotección agresiva con inhibidores de bomba de protones (IBP) más misoprostol (600 mg/día si se tolera) 19